idarucizumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
idarucizumab: clinical details
Prescribing considerations
- Confirm current or recent dabigatran exposure and that rapid reversal is clinically required for a licensed emergency indication.
- Use alongside appropriate supportive measures; idarucizumab removes dabigatran activity but does not treat the bleeding source.
- Consider resuming appropriate antithrombotic treatment once clinically stable with adequate haemostasis, because reversal exposes the underlying thrombotic risk.
- Record the product name and batch number for biological-medicine traceability.
- Account for sorbitol and sodium content, particularly in hereditary fructose intolerance.
Contraindications and cautions
- The SmPC lists no formal contraindications.
- Known hypersensitivity to idarucizumab or an excipient requires careful benefit–risk assessment in the emergency setting.
- Hereditary fructose intolerance requires careful benefit–risk assessment and intensified medical observation because the formulation contains sorbitol.
Monitoring
- Assess clinical haemostasis and continue standard bleeding or peri-procedural monitoring.
- Where informative, assess activated partial thromboplastin time, diluted thrombin time or ecarin clotting time before and after reversal.
- Monitor for recurrent bleeding or renewed dabigatran activity, particularly with renal impairment.
- Monitor for hypersensitivity and thromboembolic events.
- Transient proteinuria may occur and does not by itself indicate renal injury.
Clinical pharmacology
Idarucizumab is a humanised monoclonal antibody Fab fragment. It rapidly forms a stable complex with dabigatran and its metabolites, neutralising their anticoagulant activity. It is eliminated through renal pathways and protein catabolism.
Formulation and product differences
- The UK product is a clear to slightly opalescent, colourless to slightly yellow, ready-to-use solution for intravenous injection or infusion supplied in single-use vials.
- It contains sorbitol, sodium acetate, acetic acid, polysorbate 20 and water for injections, and requires refrigerated, light-protected storage.
idarucizumab preparations and strengths
Injection
Route: Parenteral
Strengths: 2.5 g/50 mL
idarucizumab interactions
Formal interaction studies have not been performed. Clinically important interactions are considered unlikely because idarucizumab binds very specifically to dabigatran.
Dabigatran
Idarucizumab binds and neutralises dabigatran’s anticoagulant effect; this is its intended action.
Other anticoagulants
Idarucizumab does not reverse factor Xa inhibitors, heparins, vitamin K antagonists or thrombin inhibitors other than dabigatran.
Other intravenous medicines
They must not be mixed with idarucizumab or infused simultaneously through the same intravenous access.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.